Dapagliflozin in Chronic Heart Failure : NICE guidance summary

NICE recommends dapagliflozin for chronic heart failure due to its proven efficacy in reducing the risk of cardiovascular death and heart failure hospitalization. This recommendation is based on clinical trial evidence and cost-effectiveness analysis, supporting its use within NHS resources. Dapagliflozin is a suitable treatment option, especially when considering patient preferences and healthcare inequalities.

Aspect	Details and Rationale
Indication	For adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.
Clinical Efficacy	Shown to reduce cardiovascular death and hospitalization risk.
Prescription Guidance	Should be prescribed under the advice of a heart failure specialist.
Cost-Effectiveness	Deemed cost-effective for NHS resource use.
Comparison with Other Treatments	Compared to dapagliflozin, consider cost, patient preference, and clinical effectiveness.
Primary Care Considerations	GPs should collaborate with specialists; familiarize themselves with diagnosis and management.
Socioeconomic Factors	Broad prescribing could address health inequalities.
Diagnostic Procedures	Recommends NT-proBNP measurement and echocardiography for diagnosis.
Treatment for Reduced Ejection Fraction	Also recommended for heart failure with reduced ejection fraction.

Dapagliflozin, marketed as Forxiga by AstraZeneca, has received marketing authorization for the treatment of symptomatic chronic heart failure in adults. This indication is not limited to a specific ejection fraction category. Additionally, NICE specifically recommends dapagliflozin for treating...

Try our Free Plan to get the full article.